Skip to main content
Premium Trial:

Request an Annual Quote

Epigenetic Biomarker Firm Foxo Technologies Raises $10M

NEW YORK — Epigenetic biomarker developer Foxo Technologies said on Wednesday that it has raised $10 million in private financing.

The investment round was led by Bespoke Growth Partners and brings Foxo's total amount of funding raised to date to $40 million, the Minneapolis-based company said.

Foxo said it will use the money to continue developing its bioinformatics and DNA microarray technologies for identifying epigenetic biomarkers of health and aging. The company currently offers biomarker discovery using Illumina Infinium Human and Infinium Mouse Methylation Arrays for DNA methylation testing and its MethylSuite software for epigenetic data analysis. The company is also preparing to launch a life insurance service called Foxo Life.

"The maturation of DNA sequencing technology platforms coupled with [artificial intelligence] and bioinformatic tools is creating a new era in the science of health and wellness," Foxo Founder and CEO Jon Sabes said in a statement. "We are harnessing these technologies to create proprietary, hyper-personalized epigenetic biomarkers of health and wellness that work synergistically with life insurance."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.